LON:GENI GENinCode (GENI) Share Forecast, Price & News GBX 9.25 0.00 (0.00%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range 9.01▼ 9.4050-Day Range 9.40▼ 13.2852-Week Range 6.50▼ 26Volume85,000 shsAverage Volume158,425 shsMarket Capitalization£8.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsHeadlinesOptions ChainProfileChartCompetitorsHeadlinesOptions Chain About GENinCode (LON:GENI) StockGENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test for familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test for diagnosis of hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.Read More GENI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GENI Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comGENinCode (LON:GENI) Shares Up 5.1%August 16, 2023 | marketwatch.comGENinCode Shares Rise on FDA Filing for Heart Disease Test KitOctober 3, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!July 19, 2023 | lse.co.ukGENinCode and MedStar collaborate on coronary heart disease testingJuly 19, 2023 | marketwatch.comGENinCode Collaborates With MedStar Health for Coronary Heart Disease TestJuly 14, 2023 | msn.comGenetic testing could bring in ‘new age’ of diagnostics in NHSJune 6, 2023 | lse.co.ukGENinCode annual loss widens; focuses on US, EU, and NHS in UKMay 21, 2023 | finance.yahoo.comShould You Investigate Genius Sports Limited (NYSE:GENI) At US$5.18?October 3, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 2, 2023 | lse.co.ukUK National Health Service to hike use of GENinCode heart disease testMay 2, 2023 | marketwatch.comGENinCode's Heart Disease Test Gets Accelerated Use in UK; Shares RiseJanuary 3, 2023 | lse.co.ukGENinCode shares surge amid state licence approval for California labOctober 21, 2022 | finance.yahoo.comGenius Sports (NYSE:GENI) shareholders have endured a 78% loss from investing in the stock a year agoSeptember 29, 2022 | lse.co.ukEARNINGS UPDATES: Transence Tech swings to profit; Curzon widens lossAugust 5, 2022 | ca.finance.yahoo.comGENinCode plc (GENI.L)July 8, 2022 | uk.investing.comShenzhen Techwinsemi Technology Co Ltd (001309)July 8, 2022 | uk.investing.comNordic Lights Group Oy (NORDLIG)July 3, 2022 | lse.co.ukDas (RBI): "Cryptocurrencies are a clear danger, their value is based on fantasy"July 3, 2022 | lse.co.ukUPDATE: Braemar Shipping delays publication of results; outlook goodSee More Headlines Receive GENI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GENinCode and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:GENI CUSIPN/A CIKN/A Webwww.genincode.com Phone44 1865 955 847FaxN/AEmployees34Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-6,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-84.23% Return on Assets-43.64% Debt Debt-to-Equity Ratio6.74 Current Ratio5.92 Quick Ratio15.89 Sales & Book Value Annual Sales£1.72 million Price / Sales5.15 Cash FlowGBX 11.10 per share Price / Cash Flow0.83 Book ValueGBX 5 per share Price / Book1.85Miscellaneous Outstanding Shares95,820,000Free FloatN/AMarket Cap£8.86 million OptionableOptionable Beta0.64 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Matthew Heaton Walls (Age 59)Co-Founder, CEO & Director Comp: $336.54kMr. Jordi Puig GilberteCo-Founder, COO & DirectorMr. Paul Andrew Peter Foulger (Age 53)CFO, Company Sec. & Director Comp: $150.07kKey CompetitorsgenedriveLON:GDRAbingdon HealthLON:ABDXVerici DxLON:VRCIYourgene HealthLON:YGENIntegrated DiagnosticsLON:IDHCView All Competitors GENI Stock - Frequently Asked Questions How have GENI shares performed in 2023? GENinCode's stock was trading at GBX 7.75 at the beginning of 2023. Since then, GENI stock has increased by 19.4% and is now trading at GBX 9.25. View the best growth stocks for 2023 here. What is GENinCode's stock symbol? GENinCode trades on the London Stock Exchange (LON) under the ticker symbol "GENI." How do I buy shares of GENinCode? Shares of GENI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is GENinCode's stock price today? One share of GENI stock can currently be purchased for approximately GBX 9.25. How much money does GENinCode make? GENinCode (LON:GENI) has a market capitalization of £8.86 million and generates £1.72 million in revenue each year. The company earns £-6,730,000.00 in net income (profit) each year or GBX (0.06) on an earnings per share basis. How can I contact GENinCode? GENinCode's mailing address is Oxford Science Park, John Eccles House Robert Robinson Avenue, Oxford OX4 4GP, United Kingdom. The official website for the company is www.genincode.com. The company can be reached via phone at 44 1865 955 847. This page (LON:GENI) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENinCode Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.